CCKAR
Cholecystokinin receptor type A
Also known as: CCKAR_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P32238
- Gene
- CCKAR
- Ensembl
- ENSG00000163394
- Chromosome
- 4
- Canonical length
- 428 aa
- Protein class
- FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins
- Subcellular location
- Nucleoplasm,Plasma membrane,Cytosol
OverviewNCBI Gene
This gene encodes a G-protein coupled receptor that binds non-sulfated members of the cholecystokinin (CCK) family of peptide hormones. This receptor is a major physiologic mediator of pancreatic enzyme secretion and smooth muscle contraction of the gallbladder and stomach. In the central and peripheral nervous system this receptor regulates satiety and the release of beta-endorphin and dopamine. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
428 residues, UniProt reviewed canonical sequence.
>P32238|CCKAR
1 MDVVDSLLVN GSNITPPCEL GLENETLFCL DQPRPSKEWQ PAVQILLYSL IFLLSVLGNT
61 LVITVLIRNK RMRTVTNIFL LSLAVSDLML CLFCMPFNLI PNLLKDFIFG SAVCKTTTYF
121 MGTSVSVSTF NLVAISLERY GAICKPLQSR VWQTKSHALK VIAATWCLSF TIMTPYPIYS
181 NLVPFTKNNN QTANMCRFLL PNDVMQQSWH TFLLLILFLI PGIVMMVAYG LISLELYQGI
241 KFEASQKKSA KERKPSTTSS GKYEDSDGCY LQKTRPPRKL ELRQLSTGSS SRANRIRSNS
301 SAANLMAKKR VIRMLIVIVV LFFLCWMPIF SANAWRAYDT ASAERRLSGT PISFILLLSY
361 TSSCVNPIIY CFMNKRFRLG FMATFPCCPN PGPPGARGEV GEEEEGGTTG ASLSRFSYSH
421 MSASVPPQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CCKAR can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 7
- Mean surface accessibility (rSASA)
- 0.39
- Highest tissue expression
- 27 nTPM
Expression across tissuesHPA
Tissue
- gallbladder: 27 nTPM
- stomach: 16 nTPM
- tonsil: 3.1 nTPM
- duodenum: 1.5 nTPM
- hypothalamus: 0.6 nTPM
- midbrain: 0.4 nTPM
Single-cell type
- gastric chief cells: 32 nCPM
- mucous neck cells: 25 nCPM
- parietal cells: 5.3 nCPM
- neuroendocrine cells: 2.8 nCPM
- other brain neurons: 2.7 nCPM
- oligodendrocyte progenitor cells: 1.9 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- midbrain: 15 nTPM
- hypothalamus: 11 nTPM
- thalamus: 2.7 nTPM
- medulla oblongata: 2 nTPM
- pons: 1.8 nTPM
- spinal cord: 1.7 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about CCKAR.
Disease | ImmuneIEDB
Conditions an epitope on CCKAR was assayed in.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.89
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.31
- DepMap mean gene effect
- 0.05
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- axonogenesis
- cellular response to hormone stimulus
- cholecystokinin signaling pathway
- forebrain development
- G protein-coupled receptor signaling pathway
- neuron migration
- phospholipase C-activating G protein-coupled receptor signaling pathway
- regulation of hormone secretion
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- G protein-coupled receptor, rhodopsin-like
- Cholecystokinin receptor
- GPCR, rhodopsin-like, 7TM
- 7 transmembrane receptor (rhodopsin family)
- Cholecystokinin receptor type A
- Cholecystokinin A receptor, N-terminal
- Cholecystokinin A receptor, N-terminal domain superfamily
- Cholecystokinin A receptor, N-terminal
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CCKAR as an antibody target. Whether an autoantibody or antibody against CCKAR could matter depends on whether native CCKAR is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CCKAR is annotated at the cell surface, where native CCKAR is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label CCKAR as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...